Jennifer Tjia et al have published the results of a cross-sectional study of the use of medications of “questionable benefit” in nursing home residents with advanced dementia (Tija et al, 2014). The paper forms part of the Less is More series in JAMA Internal Medicine, and also refers to the American Board of Internal Medicine Foundation’s Choosing Wisely campaign.
The list of medications of questionable benefit was decided upon and published by a panel of expert geriatricians and palliative medicine physicians as “never appropriate” for use in advanced dementia (Holmes et al, 2008). The list was designed to guide prescribing for adults with dementia and a palliative approach to care.
These “never appropriate” medications include:
- Cholinesterase inhibitors
- Some antiplatelet agents (although not aspirin)
The study population
The final study sample of 5,406 nursing-home residents was derived from a database of a US long-term care pharmacy that serves about half of the 1.3 million nursing home residents. A subset of this database can be linked with resident-level assessments from the Minimum Data Set (MDS) and comprises about 10% of the entire pharmacy database. [The MDS is part of the US federally mandated process for clinical assessment of all residents in Medicare or Medicaid certified nursing homes. This process provides a comprehensive assessment of each resident’s functional capabilities and helps nursing home staff identify health problems.]
The sample was then limited to residents over 65 with a diagnosis of advanced dementia. Advanced dementia was defined by a cognitive performance score of 5 or 6 on the MDS cognition scale. The application of these criteria led to more than half of the sample being over 85, nearly 80% female, and over 73% white.
- Nearly six out of ten people in the study sample were prescribed medication of questionable benefit
- According to the pre-published list of “never appropriate” medications, 54% of the sample were prescribed at least one of these medications
- The three most commonly prescribed were:
- Cholinesterase inhibitors (36%)
- Memantine (25%)
- Lipid lowering agents (22.4%)
- The mean 90-day cost for these medications was $816, accounting for 35% of the total 90-day expenditure on medications
Later in the paper, in the discussion section, the authors give their estimate of questionably beneficial medication use as 59%, but I have absolutely no idea where that number came from because I couldn’t find it anywhere else in the paper. I think it may have resulted from “a generalised estimating equation with a logit link function” described in the paragraph about statistical analysis. But whether it’s 54% or 59%, it is considerably higher than previous estimates of 38% in a much smaller sample of 323 nursing-home residents in the Boston area, and 29% among 34 residents in a Chicago-area palliative care program.
The investigators analysis identified a lower rate of prescription of medication of questionable benefit in residents with oral problems, a feeding tube, a “do not resuscitate” order or enrolled in hospice care. Conversely they noted that residents in homes with a high prevalence of feeding tubes were more likely to be prescribed questionable medications.
Questionable or unquestionable?
The study deliberately focussed only on those medications which were judged as “never appropriate”. I am left wondering which medications are deemed as “sometimes appropriate” and “always appropriate” for residents with advanced dementia?
A couple of the tables giving the characteristics of the nursing home residents included in the study indicated that 53% had a diagnosis of depression, and were presumably prescribed antidepressants. I wonder how a diagnosis of depression is reached in people with advanced dementia. Moreover, some of the facilities seemed to have a high level of antipsychotic use, although I found the table describing the levels of antipsychotic use in care-homes fairly indecipherable.
A personal view
From the perspective of someone with a relative with advanced vascular dementia, I think all medications are of questionable value if they have side effects which might have a negative impact on quality of life or are likely to cause harm. For example, my mother is still being prescribed an antidepressant. Her diagnosis of depression in 2010 was given before long before the diagnosis of dementia. She has been on several types of antidepressant medication since 2010 and her diagnosis of dementia came late in 2011, and it now seems inconceivable that she should ever stop taking it, despite no evidence of benefit and some evidence of harm reported in the literature.
The accompanying invited commentary by Greg Sachs (Sachs, 2014) expresses the wish that the results of this study are not just read by clinicians looking after people with advanced dementia, but by all physicians looking after older people. The commentary urges more thoughtful and common-sense prescribing practices amongst all those treating older patients with a limited life expectancy, where comfort and dignity is likely to be the main goal of care.
What’s less clear is how this wishful thinking is going to translate into reality. My view is that it cannot be left to clinicians working against the tide of entrenched and conventional prescribing practices with little incentive to change. Patients and their carers should be also be empowered with the knowledge and confidence to question the benefit of medications themselves and work in partnership with clinicians to change prescribing practices. Not easy, but essential.
Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of Medications of Questionable Benefit in Advanced Dementia. JAMA Intern Med. doi:10.1001/jamainternmed.2014.4103 Published online September 8, 2014. [Abstract]
Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, et al. (2008) Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. Journal of the American Geriatrics Society.56: 1306–11. [PubMed abstract]
Sachs GA. Improving Prescribing Practices Late in Life: A Task for all Clinicians, Not Just Nursing Home Physicians. JAMA Intern Med.Published online September 08, 2014. [Abstract]
RT @Mental_Elf: Medication in advanced dementia: how can we judge what is appropriate? http://t.co/xryJjNO38X
Medication in advanced dementia: how can we judge what is appropriate?: Caroline Struthers appraises a recent … http://t.co/bPa5e0k8w8
Today @ALOIScommunity on a study of the use of medications of “questionable benefit” in ppl with advanced dementia http://t.co/qRwfHsyC4T
.@alzheimerssoc Medication in advanced dementia: what’s appropriate? http://t.co/qRwfHsyC4T Pls comment and RT
The Mental Elf liked this on Facebook.
Should we be prescribing cholinesterase inhibitors, memantine or lipid lowering agents to ppl with advanced dementia? http://t.co/qRwfHsyC4T
.@DementiaUK @dementiacentre @FisherCenter Medication in advanced dementia: what’s appropriate? http://t.co/qRwfHsyC4T Pls comment and RT
US study finds nearly 6 out of 10 people with advanced dementia were prescribed medication of “questionable benefit” http://t.co/qRwfHsyC4T
@Mental_Elf Very uncomfortable about this study. Meds to slow decline in dementia shouldn’t be stopped just because in care home.
@HilaryMarmot @Mental_Elf Just seen this other tweet. yes, I agree with you entirely. But I don’t think the study is advocating that.
@ALOISCommunity @Mental_Elf I would happy if they had decided that antipsychotic drugs or benzodiazepines should be prescribed less.
@ALOISCommunity @Mental_Elf I do admit that I have been too lazy to actually read the paper!
@HilaryMarmot @Mental_Elf Yet another observational study containing academic jargon and euphemisms aplenty leading to too little change
@Mental_Elf Much of the ‘cost benefit’ studies done to show delay to nursing home. Would be wrong to allow decline just because of this.
@gerisoc of interest? US study: ~ 6/10 w/ advanced dementia prescribed meds of “questionable benefit” http://t.co/Zj19KUimSV via @Mental_Elf
Good take on prescribing in dementia #lessismore @GeriSoc @NHS_GP @adamgordon1978 @rcgp @ajpcarr @geri_baby http://t.co/Cabj4nFABM
There is evidence that acetycholinesterase inhibitors are effective in moderate to severe dementia. http://www.medscape.com/viewarticle/766524_2. They can help a little with cognitive problems and more importantly with psychological problems. Much of the research assessing benefits in dementia drugs use ‘delay in time needed before going into care home’ to measure cost effectiveness of the drugs http://onlinelibrary.wiley.com/doi/10.1046/j.1524-4733.2001.40202-235.x/abstract I am not comfortable with the idea that once in a care home drugs which may be slowing decline in memory and may be having psychological benefits should be stopped. Donepezil may also prolong life.http://www.biomedcentral.com/1471-2377/14/83. It feels a bit like euthanasia to me.
Mental Elf: Medication in advanced dementia: how can we judge what is appropriate? http://t.co/FmgRA2R2Gy
Dementia patients & carers should be empowered with knowledge & confidence to question benefit of medication http://t.co/qRwfHsyC4T
Don’t miss: Medication in advanced #dementia. How can we judge what’s appropriate? http://t.co/qRwfHsyC4T
@Mental_Elf interesting read
Medication in advanced #dementia: how can we judge what is appropriate? http://t.co/QcQixwvg1u New blog from @Mental_Elf
@Mental_Elf asks: Medication in advanced #dementia. How can we judge what’s appropriate? http://t.co/zOOg7sEcQB